Mary Ellen Perry, Ph.D., Program Leader Office of Strategic Coordination

1. Special NIH Funding Opportunities Mary Ellen Perry, Ph.D., Program Leader Office of Strategic Coordination Division of Program Coordination, Planning, and Strategic Initiatives NIH Office of the Director

2. 27 NIH Institutes and Centers Clinical Center National Institute of Deafness and Communications Disorders NIAMS National Institute of Arthritis and Musculoskeletal and Skin Diseases International Center National Institute of Biomedical Imaging and Bioengineering National Institute of Diabetes and Digestive and Kidney Diseases

3. The Office of the Director (OD)

4. Strategic Priorities • High-throughput Technologies • Translational Medicine • Science for Health Care Reform • Global Health • Reinvigorating and Empowering the Biomedical Research Community Francis S. Collins, M.D., Ph.D. NIH Director

5. Established: • the Common Fund to support cross-cutting, trans-NIH programs • the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI)

6. In FY2010, the Common Fund was $544M. • The Common Fund currently supports a series of short term, high impact, trans-NIH programs, some of which were previously called Roadmap programs. James M. Anderson, M.D., Ph.D. DPCPSI Director

7. 27 active programs! 2009 BC

8. Five Special Funding Opportunities Eureka!

9. Reinvigorating and Empowering the Biomedical Research Community We must develop ways to liberate our brightest minds to pursue high-risk, high-reward ideas during their most creative years. Nature, Vol.467, 7 October 2010.

10. Age Distribution of R01-equivalent Principal Investigators AllInvestigators First-Time Investigators FY2007 Data Average Age All Investigators 51.0 First-Time Investigators 42.6 Percent of Total Age

11. How can we shorten the time to first grant? GRADUATE/ MEDICAL STUDENT POST DOCTORAL GRADUATE/ MEDICAL STUDENT EARLY EARLY MIDDLE MIDDLE CAREER CAREER SENIOR SENIOR

12. Early Independence Award Program • Graduate students and clinicians within one year of degree • Up to $250K DC/year for five years, plus F&A • Talented young scientists who have the intellect, scientific creativity, drive and maturity to flourish independently without the need for traditional post-doctoral training • FOA RM10-019 • January 21, 2011 receipt http://nihroadmap.nih.gov/

13. Reinvigorating and Empowering the Biomedical Research Community New Innovator programaddresses two important goals: stimulating highly innovative research and supporting promising new investigators (167 awards since 2007). Pioneer Awards support individual scientists of exceptional creativity who propose pioneering approaches to major challenges in biomedical and behavioral research (98 awards since 2004). Transformative R01 program places the emphasis on creative ideas - projects with the potential to create or overturn paradigms (62 awards since 2009). http://nihroadmap.nih.gov/

14. New Innovator Award • Unusually creative investigators with a highly innovative research idea • $300K DC/year for five years, plus F&A • New and early stage investigators • FOA RM10-009 • Due date September 20, 2010 452 applications http://nihroadmap.nih.gov/

15. New Innovators in cancer research Jianjun Cheng University of Illinois at Urbana-Champaign Developing Clinically Applicable, Cancer-Targeting Polymeric Nanoconjugates Conor Evans Massachusetts General Hospital/Harvard Medical School Imaging and Overcoming Hypoxia-Induced Resistance in Metastatic Ovarian Cancer Monica Guzman Cornell University /Weill Medical College Selection of Novel Therapies to Ablate Chemoresistant Myeloid Leukemia Stem Cells Benjamin Garcia Princeton University Novel Methodology for Quantitative High-throughput Cancer Epigenetics http://nihroadmap.nih.gov/

16. Pioneer Award Program • Any qualified investigator • $500K DC/year for five years, plus F&A • Individual scientists of exceptional creativity who propose pioneering and possibly transforming approaches to addressing major biomedical or behavioral challenges • FOA RM10-008 • Due date September 13, 2010 240 applications http://nihroadmap.nih.gov/

17. Some Pioneers of interest Leona Samson Massachusetts Institute of Technology Developing Novel Methods to Measure DNA Repair Capacity in Human Populations Michael Roukes California Institute of Technology Nanoscale Tools to Push Biomedical Frontiers Susan Rosenberg Baylor College of Medicine Forward Genomics of Damage Control: An Undiscovered Class of Cancer Genes Joseph Nadeau The Institute for Systems Biology Lamarck Redux: Transgenerational Genetic Effects on Phenotypes and Disease http://nihroadmap.nih.gov/

18. Transformative RO1 • Anyone with a project to overturn or create a paradigm • Up to $25M TC for five years • “Out of the box” ideas • FOA RM10-010 • October 27, 2010 receipt http://nihroadmap.nih.gov/

19. Some TRO1 projects of interest GEORGE COUKOS University of Pennsylvania Transformative Personalized Vascular Disrupting Cancer Immunotherapy RICHARD FLAVELL MADHAV DHODAPKAR MARKUS MANZ Yale University and University Hospital Zurich Understanding Hematopoietic Neoplasias Using Humanized Mice http://nihroadmap.nih.gov/

20. Reinvigorating and Empowering the Biomedical Research Community New Innovator Programaddress two important goals: stimulating highly innovative research and supporting promising new investigators (167 awards since 2007). We WILL have all 3 competitions again next year! Look for announcements next spring. http://nihroadmap.nih.gov/ Pioneer Awards support individual scientists of exceptional creativity who propose pioneering approaches to major challenges in biomedical and behavioral research (98 awards since 2004). Transformative R01 Program places the emphasis on creative ideas—projects with the potential to create or overturn paradigms. (62 awards since 2009).

21. Trans-NIH but not Common Fund • Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) Program • Open to anyone with a high impact project • “Exceptionally innovative research on novel hypotheses or difficult problems, solutions to which would have an extremely high impact on biomedical or bio-behavioral research” • Up to $800K DC for four years, plus F&A • FOA GM10-009 • November 24, 2010 receipt

22. Institutes participating in EUREKA awards

23. NCI Eureka awardee 2010 “Our plan is to deliver the tumor to the drug -- by directing tumor cells to a specially engineered gel that can be removed or designed to kill the cells -- rather than the current strategy of delivering the drug to the tumor, which is problematic due to the irregular vasculature and poor diffusivity of the tumor tissue,” explained Bellamkonda, who is also a Georgia Cancer Coalition Distinguished Scholar. Ravi Bellamkonda, Ph.D. Georgia Institute of Technology

24. Summary Special Opportunities Program Eligibility Early Independence Award Graduate student or new clinician New Innovator New PI/ESI with innovative project Pioneer Very creative investigator TR01 Person with paradigm – disrupting idea Eureka award Person with a very innovative project

26. For more information: http://nihroadmap.nih.gov/ Contact information: Today’s talk – Mary Ellen Perry perryma@mail.nih.gov Pioneer, TR01, New Innovators, Early Independence Award – Ravi Basavappa basavapr@od.nih.gov Eureka awards – Judy Mietz mietzj@mail.nih.gov Common Fund – Ellie Murcia murciae@od.nih.gov